

1624

RECEIVED
By _____
(Signature of person mailing)
Julie Gozino
(Typed or printed name of person)

NOV 18 2003

TECH CENTER 1600/2900

Patent Application
Attorney Docket No. 0004-07-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Värney et al.

APPLICATION NO.: 10/047,935

Examiner: Bruck Kifle

FILING DATE: 10/23/2001

Group Art Unit: 1624

TITLE: ANTIPIROLIFERATIVE SUBSTITUTED
5- THIAPYRIMIDINONE AND 5-
SELENOPYRIMIDINONE
COMPOUNDS

Hon. Commissioner of Patents

Mail Stop: AF

P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

REVISED TERMINAL DISCLAIMER

Further to the Terminal Disclaimer filed on August 1, 2003, we herewith submit a corrected Terminal Disclaimer. Agouron Pharmaceuticals Inc. is the owner of 100% interest in the above-captioned application and in U.S. Patent 5,739,141 as evidenced by the copies of the relevant Assignment documents attached hereto. Agouron Pharmaceuticals Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173 as shortened by any terminal disclaimer filed in U.S. Patent 5,739,141. The owner hereby agrees that any patent so granted

on the above-captioned application shall be enforceable only for and during such period that U.S Patent 5,739,141 is commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of U.S. Patent 5,739,141, as presently shortened by any terminal disclaimer, in the event that U.S. Patent 5,739,141 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date: November 5, 2003

Wendy L. Hsu
Wendy L. Hsu
Attorney for Applicants
Reg. No. 42,794

Agouron Pharmaceuticals Inc./
A Pfizer Company
10777 Science Center Drive
San Diego, CA 92121
Phone: (858) 526-4652
FAX: (858) 678-8233

Art Unit: 1624

harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 62 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7, 23-25 and 32 of U.S. Patent No. 5,739,141. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instantly claimed species are embraced by the generic claims of the reference. The reference teaches a generic group of compounds which embraces applicant's instantly claimed compounds. See formula I, II, III or X in reference claims, the instantly claimed compounds fall within the reference genus. The compounds are taught to be useful as antiproliferative agents, see the claims. The instant claim differs from the reference by reciting specific species that fall within the reference genus. It would have been obvious to one having ordinary skill in the art at

SUBJECT: DECISION ON TERMINAL DISCLAIMERS FORMAL FORM

DATE: 1-29-04

APPL. S.N.: 101047935

TO EXAMINER: B. Kifke

ART UNIT: 1624

MOSE MONTGOMERY, ROOM 11E18

MAILROOM DATE 11-10-03

AFTER FINAL YES NO NUMBER OF T.D(S). FILED 1

INSTRUCTIONS: I have reviewed the submitted T.D. with the results as set forth below. If you agree, please use the appropriate form paragraphs identified by this Informal memo in your next office action to notify applicant about the T.D. If you disagree with my analysis or have questions at all about the acceptability of the T.D., please see me or our Special Program Examiner. THIS MEMO IS AN INFORMAL, INTERNAL MEMO ONLY. IT MUST NOT BE MAILED TO APPLICANT, NOR SHOULD A COPY BE IN LEFT IN FILE.

The T.D. is PROPER and has been recorded. (See 14.23).

The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24).

The recording fee of \$110.00 has not been submitted nor is there any pre authorization in the application file to charge to a deposit account. (See 14.26.07)

Application Examiner has not processed T.D. fee. (See fee authorization).

The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent. (See 14.26 and 14.26.01).

The T.D. lacks the enforceable only during the common ownership clause needed to overcome a double patenting rejection, Rule 321(c). (See 14.27, 14.27.01).

It is directed to a particular claims(s), which is not acceptable since "the disclaimer must be of a terminal portion of the term of the entire patent to be granted". MPEP 1490. (See 14.26, 14.26.02).

The person who signed the terminal disclaimer:

has failed to state his/her capacity to sign for the business entity. (See 14.28).

is not recognized as an officer of the assignee. (See 14.29 and possibly 14.29.01).

No documentary evidence of a chain of title from the original inventor(s) to assignee has been submitted, nor is the reel and frame specified as to where such evidence is recorded in the office. 37 CFR 3.73(b). (See 1140 O.G. 72). NOTE: This documentary evidence or the specifying of the reel and frame may be found in the T.D. or in a separate paper submitted by applicant. (See 14.30).

No "statement" specifying that the evidentiary documents have been reviewed and that, to the best of the assignee's knowledge and belief the title is in the assignee seeking to take action. 37 CFR 3.73(b). (See 1140 O.G. 72) (See 14.31).

The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if TD is not signed by all the owners.

Attorney not of record in oath/decl. or a separate paper filed appointing a new or associate attorney. (See 14.29.01).

The serial number of the application (or the number of the patent) which forms the basis for the double patenting is missing or incorrect. (See 14.32).

The serial number of this application (or the number of the patent in reexam or reissue case(s) being disclaimed is missing or incorrect. (See 14.26, 14.26.04 or 14.26.05).

The period disclaimed is incorrect or not specified. (See 14.27, 14.27.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)

Other: _____

Suggestion to request refund of \$ _____. (See 14.35, 14.36).

EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR ALLOWANCE ANY OF THE ABOVE INFORMALITIES MAY BE FAXED IN TO THE GROUP

FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:

Sample of a TD over a pending application and assignee Certificate (See 14.37).

Sample of a TD over a prior patent and assignee Certificate (See 14.38).

Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39)